Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding$1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.

Biotechnology

Health Care

Health Diagnostics

Alzeca Biosciences

Alzeca Biosciences' headquarters in Houston, TX, United States

Carlo Medici

Joseph Jankovic

Michael Weiner

Peter J. Werth

Stephen C. Cook

Scott W. Atlas

Jason Eriksen

Ananth Annapragada

Navneet Puri

Shane Brisbin

Peter Working

David S. Knopman

Adriano Aguzzi

Description

People (1)

Jason Eriksen

Jobs